Akili Interactive Completes $55 Million in Financing
Akili Interactive, a prescription digital medicine company developing treatments for cognitive dysfunction, closed a $55 million Series C financing round led by Temasek. Other participating institutional and strategic investors included Baillie Gifford, Amgen Ventures, M Ventures (the CVC fund of Merck KGaA, Darmstadt, Germany), JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies.
According to the company, the financing follows positive top-line results in 2017 of a multicenter, randomized, controlled pivotal study of AKL-T01, Akili’s flagship investigational product designed to treat pediatric attention deficit/hyperactivity disorder (ADHD). Akili is planning to file AKL-T01 for clearance by the U.S. Food and Drug Administration in the coming months, which would enable it to be prescribed by physicians as a stand-alone treatment for children and adolescents with ADHD. If approved, AKL-T01 would be the first prescription digital treatment for pediatric ADHD.